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INTRODUCTION
Omeprazole and pantoprazole are substituted benzimi-
dazole derivatives. These agents, which are activated in
the acidic compartment of the parietal cell, inhibit
gastric acid secretion by binding to active proton pumps
(H+-, K+-ATPase) in the secretory membrane of the
parietal cell. The duration of the inhibitory effect of
these drugs is due to the prolonged binding to the
proton pump.1–3 Substituted benzimidazole derivatives
are rapidly eliminated from plasma and are extensively
metabolized by cytochrome P-450 enzymes in the
liver.3, 4
Recently omeprazole became available in a tablet
formulation, a Multiple Unit Pellet System (MUPS),
which contains a large number of small individually
enteric-coated micropellets of omeprazole. MUPS tablets
disintegrate rapidly in the stomach and the micropellets
may empty more easily into the duodenal channel than
conventional enteric-coated tablets.5, 6 The relatively
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new proton pump inhibitor pantoprazole is adminis-
tered as an enteric-coated tablet.
The recommended dose of omeprazole for the treat-
ment of peptic ulcer disease and reflux disease is 20 or
40 mg o.d. The standard dose pantoprazole for both
indications is 40 mg q.d.s. The pharmacodynamics of
omeprazole capsules and pantoprazole tablets have been
compared in several studies. Hartman et al. compared
omeprazole 20 mg capsules with pantoprazole 40 mg
tablets in a crossover study in healthy subjects with an
unknown Helicobacter pylori status.7 To make the study
double-blind, two tablets of pantoprazole (20 mg) or
one capsule of omeprazole (20 mg) were encapsulated
using identical hard gelatine capsules. In that study
pantoprazole 40 mg was significantly more effective
than omeprazole 20 mg in raising 24-h median pH and
daytime median pH both after single and repeated
administration. However, with respect to healing rate,
omeprazole 20 mg capsules and pantoprazole 40 mg
tablets have similar efficacy in the treatment of reflux
oesophagitis and duodenal ulcer.8, 9
The aim of the present study was to compare the
pharmacodynamic effect on gastric pH of omeprazole
MUPS 20 mg with pantoprazole 40 mg enteric-coated
tablets following single (day 1) and repeated (day 6) oral
administration and to describe the pharmacokinetics of
both medications on these days.
METHODS
Subjects
Healthy subjects, between 18 and 40 years old, with
normal physical examination and laboratory screening
tests (haemoglobin, white blood cell total count, serum
glucose, serum creatinine, total bilirubin, serum alka-
line phosphatase, serum ASAT and/or ALAT) were
recruited for the study. They were eligible for inclusion if
their H. pylori serology (ELISA) was negative, and if
their 24-h baseline gastric pH measurement was
< pH 4 for more than 70% of the time (more than
16.8 h) at the time of enrolment.10 Individuals were
excluded from the study if they were pregnant, if they
had gastrointestinal disorders, which might impair drug
absorption, if they had a body weight more than 15%
from ideal, and if they had a history of alcohol or drug
abuse.
With the exception of oral contraceptives and the
occasional use of paracetamol (acetaminophen) the
subjects took no medication other than the study
medication. Smokers were not excluded, but were
instructed to refrain from smoking during the pH-
monitoring studies. All subjects gave written informed
consent and the study was conducted in accordance
with the Declaration of Helsinki. The local Ethics
Committee approved the study protocol.
Study protocol
This was a randomized, two-way crossover, investigator-
blind study performed in the Leyenburg Hospital from
April 1998 to October 1998. The study was designed to
include 16 healthy H. pylori-negative subjects whose
intragastric pH was below pH 4 for more than 70% of
the time during a 24-h baseline period.
After inclusion each subject was assigned to one of the
two 6-day dosing periods during which the subject
received either omeprazole MUPS 20 mg o.d. or panto-
prazole 40 mg o.d. Dosing periods were separated by
washout periods of at least 14 days. The effect of both
drugs on gastric acidity was assessed by 24-h intragas-
tric pH monitoring on day 1 and day 6 of administration.
During the days of pH monitoring subjects stayed at a
special research room in the clinic. Subjects arrived at
the pH laboratory of the clinic by 08:00 hours. A
venous catheter was inserted and the first blood sample
was drawn. A nostril was anaesthetized with xylocaine
spray and the ‘personal’ pH-measuring assembly was
inserted and positioned, such that the pH electrode was
located in the gastric corpus, 5–10 cm below the
oesophagogastric junction as determined by the pH-
drop. The insertion depth was recorded. In subsequent
pH studies in the same subject, this same insertion depth
was used. Recordings started at 08:30 hours. After the
pH recording was started, the subjects took the first dose
of the study medication immediately before the standard
breakfast. Standard meals (breakfast, lunch and dinner)
were prepared in the hospital and subjects were
instructed to eat their lunch at 14:00 hours, and dinner
at 18:00 hours. Blood samples (5 mL) for determination
of omeprazole and pantoprazole plasma concentrations
were drawn at pre-dose and at 30, 45, 60, 90, 120,
150, 180, 210 min, and at 4, 5, 6, 7, 8 and 9 h after
dose. The venous catheter was removed after the last
blood sample. From 23:00 hours the subjects remained
in fasting condition and slept. They arose again between
07:00 and 07:30 hours the next day. The pH electrode
was removed at 08:30 hours and the position of the
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assembly was checked prior to removal. On the pH
measurement days the use of tap water, tea and non-
carbonated mineral water was restricted to a total of
2 L. Other beverages were not permitted.
Plasma concentrations of omeprazole and pantopra-
zole were determined by means of liquid chromatogra-
phy techniques at Bio-analytical Chemistry, Astra
Ha¨ssle AB, Mo¨lndal, Sweden.11
Data analysis and statistical evaluation pH data
Twenty-four-hour pH-metry was performed as previ-
ously described.12
Evaluation of pH data was performed as previously
described.12, 13 Data were analysed using the SPSS
statistical package. Wilcoxon’s matched pairs signed
rank test was used for comparison between treatment
regimens. Median pH values over the whole 24-h
period, day- and night-time, and cumulative percent-
ages of time during which pH was above thresholds
3 and 4 over these time periods, were compared.
The significance level of each test was set at 0.05 (two-
sided). P-values are presented as calculated for each test,
no correction being made for multiple testing.
Pharmacokinetic data
Pharmacokinetic parameters were derived by non-
compartmental analysis using WinNonlin software
(version 3.1, Scientific Consulting Inc.). For each
individual the following parameters were derived sepa-
rately on day 1 and 6 of drug administration: time prior
to the first measurable concentration (Tlag), time of
maximum observed concentration (Tmax), and the
maximum observed concentration (Cmax). The terminal
rate constant (k) was determined by log-linear regres-
sion of the terminal phase of the plasma concentration–
time curve. The terminal half-life (T) was calculated as
follows: T  0.693/k. The area under the concentra-
tion–time curve (AUC) and the area under the first
moment curve (AUMC) were estimated by the linear-
logarithmic trapezoidal method up to the last measured
data point with extrapolation to infinity using k. The
ratio of plasma clearance and bioavailability (Cl/F) was
calculated by dividing the dose by the AUC. The ratio of
the volume of distribution based on the terminal phase
and bioavailability (V/F) was calculated by dividing Cl/
F by k. Mean residence time (MRT) was the ratio of
AUMC and AUC.
Differences in pharmacokinetic parameters between
day 1 and 6 and differences in pharmacokinetic
parameters between omeprazole and pantoprazole were
evaluated using Wilcoxon’s matched pairs signed rank
test. The level of significance was set at 0.05.
RESULTS
Eighteen healthy subjects (11 women, seven men, aged
20–30 years) were screened. The serology (ELISA) was
positive in one subject. One subject discontinued with
the study after the baseline measurement. Sixteen
subjects (nine women, seven men) with a mean age of
24.7 years (range 21.4–30 years), a mean weight
of 73 kg (range 55–97 kg) and a mean height of
175.6 cm (range 157–192 cm) fulfilled the inclusion
criteria and were randomized. Both drugs were well-
tolerated and there were no clinically relevant adverse
events.
Group median pH-time curves and interquartile ranges
(25th–75th percentile) for baseline and the two treat-
ment regimens during the first (day 1) and second (day
6) 24-h recording period are shown in Figure 1. The
percentages of time spent above pH thresholds 1–7 for
baseline and the two treatment regimens during the
entire recording period, day- and night-time on day 1
and day 6 are shown in Figure 2. Inter-individual
variation in response to the different dosing regimens is
shown in Figure 3. Median pH values and median
percentages of time spent above pH thresholds 3 and 4,
for baseline and the two treatment regimens during the
entire recording period, and day- and night-time on day
1 and day 6 are shown in Table 1. Differences in
pharmacokinetic parameters between day 1 and 6 and
differences in pharmacokinetic parameters between
omeprazole and pantoprazole are displayed in Table 2.
Median plasma concentrations of omeprazole and
pantoprazole on day 1 and day 6 of administration
are shown in Figure 4.
Compared to baseline, both drugs significantly
increased median gastric pH and the percentages of
time spent above pH 3 and 4 over the whole first 24 h
of administration. During the night-time period, per-
centages of time above pH thresholds 3 and 4 were not
significantly increased with pantoprazole. There were
no significant differences between omeprazole and
pantoprazole in median pH values or time spent above
pH thresholds 3 and 4 for either the whole first 24 h
period or day- or night-time period. On day 6 of
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administration, median pH over the day period was
significantly higher with omeprazole MUPS, but there
were no significant differences between omeprazole and
pantoprazole in the percentages of time spent above pH
thresholds 3 and 4.
On day 6 of omeprazole administration, Cmax, T, and
AUC were significantly increased in comparison with the
values on day 1, whereas Cl/F and V/F were reduced. No
pharmacokinetic differences were observed between day
1 and day 6 of administration for pantoprazole. Tlag and
T of omeprazole were smaller than the corresponding
values of pantoprazole. No significant differences were
observed for Tmax and MRT on day 1 and day 6, between
omeprazole and pantoprazole.
DISCUSSION
This direct comparative study in H. pylori-negative
subjects showed no significant differences between
omeprazole MUPS 20 mg and pantoprazole 40 mg after
Figure 1. pH–time curves for baseline and the two treatment periods (day 1 and day 6 of administration). Median pH and 25th–75th
percentile (shaded area). Arrows: L  lunch, D  dinner.
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single dose administration. After repeated administra-
tion median pH over the day period was significantly
higher with omeprazole MUPS, but there were no
significant differences between omeprazole and panto-
prazole in the percentages of time spent above pH
thresholds 3 and 4.
The pharmacokinetic parameters in this study are
consistent with data obtained in other studies for both
omeprazole and pantoprazole.6, 14, 15 The time interval
between dosing and the first measurable concentration
of omeprazole MUPS was significantly shorter than the
lag time of pantoprazole, but there was no significant
difference in acid-inhibitory effect during the daytime on
day 1 of administration. AUC and Cmax of omeprazole
MUPS 20 mg were significantly higher on day 6 than
on day 1 (74% and 68%, respectively). This effect has
been described earlier.14, 15 Possible reasons for the
increase in bioavailability upon repeated administration
may be saturation of first-pass metabolism and a
stepwise decrease in gastric acid delivered into the
duodenum.16 The increased bioavailability and
decreased clearance is reflected in the decrease in V/F
and Cl/F. For pantoprazole, AUC and Cmax following
repeated administration were comparable to those after
the first dose, indicating that bioavailability remained
constant after the first dose. The clinical relevance of the
increase in AUC with repeated dosing of omeprazole
remains unclear. However, it can be speculated that the
increase in AUC may contribute to the increase in the
pharmacodynamic effect on day 6 of administration.
In the present study median gastric pH on day 6 over
the daytime period was significantly higher with
omeprazole MUPS. In a previous direct comparative
study of omeprazole MUPS 20 mg and pantoprazole
40 mg, median gastric pH on day 7 of administration
was not significantly different. However, on day 1,
median gastric pH was significantly higher with pan-
toprazole.17 The clinical relevance of significant differ-
ences in median pH over time periods is limited, when
percentages of time spent above pH thresholds 3 and 4
in those time periods do not differ significantly. Accord-
ing to the studies of Burget, Bell and Howden et al.,
healing of peptic ulcer disease or erosive oesophagitis
with antisecretory drugs is correlated with both the
duration of gastric acid suppression over the 24-h
Figure 2. Cumulative percentages of time spent above pH
thresholds during time periods. D1  day 1, D6  day 6, ome
20  omeprazole MUPS 20 mg, pan 40  pantoprazole 40 mg.
Figure 3. Individual responses of the 16 subjects to omeprazole
MUPS 20 mg o.d. and pantoprazole 40 mg o.d. on day 1 and day
6 of administration (24-h period). D1  day 1, D6  day 6, ome
20  omeprazole MUPS 20 mg, pan 40  pantoprazole 40 mg.
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period and the degree of gastric acid suppression.18–20
The percentage of time spent above pH threshold 3 is
more important for ulcer healing than further elevation
of gastric pH. Healing rates at 8 weeks of (erosive) reflux
oesophagitis are directly correlated with the duration of
gastric acid suppression above pH 4. In our study there
is no significant difference between omeprazole MUPS
20 mg and pantoprazole 40 mg in the percentages of
time spent above pH 3 and 4 on day 1 and day 6 of
administration. The percentages of time spent above
pH 3 and 4 on day 6 of omeprazole 20 mg MUPS
administration are comparable with the values of these
variables found in a previous study with omeprazole
20 mg capsules.12 This indicates that the omeprazole
20 mg MUPS formulation performs as well as the
omeprazole 20 mg capsules formulation. Therefore, it is
not surprising that in clinical studies omeprazole 20 mg
capsules and pantoprazole 40 mg tablets have similar
efficacy with respect to healing rates in the treatment of
duodenal ulcer and reflux oesophagitis.8, 9 Further-
more, more recently Mulder et al. showed that ome-
prazole MUPS 20 mg and pantoprazole 40 mg have
similar efficacy in symptom relief at 4 weeks in the
treatment of reflux oesophagitis grade I to IV.21
In conclusion, this direct comparative study demon-
strates that the acid-inhibitory effects of omeprazole
MUPS 20 mg and pantoprazole 40 mg are not signifi-
cantly different on day 1 of administration. On day 6 of
administration, median daytime pH was significantly
higher with omeprazole MUPS. The clinical relevance of
Table 1. Pharmacodynamic data of omeprazole MUPS 20 mg and pantoprazole 40 mg. Median pH values, median percentage of time

















24 h 1.6 (1.5–1.9) 1.95 (1.7–3.7) 2.4 (1.8–3.7) 0.178 4.05 (3.5–4.7) 3.7 (2.9–4.5) 0.289
night 1.5 (1.3–2.2) 2.0 (1.6–2.8) 2.3 (1.6–2.75) 0.234 3.3 (2.0–5.2) 3.05 (2.1–4.0) 0.469
day 1.84 (1.6–2.0) 2.1 (1.7–4.0) 3.0 (1.9–4.2) 0.125 4.65 (3.6–5.0) 4.05 (3.2–4.8) 0.038
% > pH 3
24 h 22.4 (16.3–26.6) 31.3 (22.8–56.6) 41 (25.4–62) 0.148 69.5 (53.4–79.5) 61 (49–74.5) 0.569
night 12.8 (5.0–35.8) 33.2 (14.5–48) 33.9 (7.3–46.2) 0.796 57.1 (19.2–65.3) 50.8 (24.9–71.3) 0.959
day 23.7 (19.2–29.5) 36.9 (26.3–64.3) 50 (33.8–72.3) 0.07 82.2 (60.1–88.1) 65.2 (54.4–85.6) 0.255
% > pH 4
24 h 11.9 (9.5–17.7) 20.8 (14.9–44.7) 29.5 (18.4–43.7) 0.109 51.9 (43.1–62.2) 46.4 (31.2–61.5) 0.438
night 8.3 (1.2–26.5) 22.5 (6.5–32.1) 20.1 (0.2–30) 0.056 41.0 (12.4–56.3) 39.3 (16.7–49.9) 0.836
day 13.1 (9.0–15.9) 23.6 (15.3–49.9) 39.3 (25.3–55.8) 0.1 68.9 (42.5–74.1) 51.2 (36–69.3) 0.109
Table 2. Pharmacokinetic data of omeprazole MUPS 20 mg and pantoprazole 40 mg. Median values and interquartile ranges (25th–
75th percentile)
Omeprazole MUPS Omeprazole MUPS Omeprazole MUPS Pantoprazole Pantoprazole
Day 1 Day 6 Day 1 vs. day 6 Day 1 Day 6*
Tlag (h) 0.0§ (0.0–0.56) 0.0  (0.0–0.25) 0.724 0.63§ (0.5–1.00) 0.5  (0.0–1.31)
Tmax (h) 0.75 (0.5–2.5) 0.75 (0.5–1.5) 0.636 1.5 (0.94–2.00) 1.0 (1.0–3.25)
Cmax 0.47 (0.2–0.64) 0.79 (0.59–0.84) 0.003 2.69 (2.4–3.39) 3.29 (2.30–3.55)
AUC (mg Æ h/L) 0.65 (0.38–1.00) 1.13 (0.83–2.01) 0.001 4.34 (3.13–7.04) 4.21 (2.58–6.27)
Cl/F (L/h) 31 (18–52) 18 (10–25) 0.008 9.2 (5.7–12.8) 9.5 (6.2–15.5)
V/F 31 (25–41) 21 (19–26) 0.001 17 (13–22) 16 (11–23)
T (h) 0.81à (0.64–1.00) 0.91# (0.75–1.39) 0.047 1.33à (1.12–1.49) 1.11# (1.00–1.34)
MRT (h) 2.2 (1.7–3.4) 1.8 (1.6–3.2) 0.438 2.8 (2.2–3.8) 2.6 (2.1–5.6)
* For pantoprazole no significant differences between day 1 and day 6.
P-values omeprazole vs. pantoprazole: § = 0.011;   = 0.03; à = 0.001; # = 0.001.
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this difference is limited, since percentages of time spent
above pH 3 and 4 in this period were not significantly
different. The significant increase in bioavailability of
omeprazole on day 6 of administration may contribute
to the increased acid-inhibitory effect after repeated
administration.
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